vTv Therapeutics (NASDAQ:VTVT) Shares Cross Below Fifty Day Moving Average - Here's What Happened

Key Points

• vTv Therapeutics shares fell below the 50-day moving average of $16.63, closing at $16.21 with a trading volume of 1,258 shares.
• Analysts have mixed ratings on vTv Therapeutics, with HC Wainwright assigning a "buy" rating and a target price of $36.00, while Wall Street Zen initiated coverage with a "sell" rating.
• The company reported an earnings per share loss of ($0.77) for the last quarter, missing analysts' expectations of ($0.73) by a margin of ($0.04).

vTv Therapeutics Inc. (NASDAQ:VTVT - Get Free Report)'s stock price passed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $16.63 and traded as low as $16.57. vTv Therapeutics shares last traded at $16.21, with a volume of 1,258 shares traded.

Analyst Upgrades and Downgrades

VTVT has been the topic of several research analyst reports. Wall Street Zen initiated coverage on shares of vTv Therapeutics in a research report on Wednesday, April 16th. They set a "sell" rating on the stock. HC Wainwright assumed coverage on shares of vTv Therapeutics in a research note on Wednesday, April 9th. They set a "buy" rating and a $36.00 price objective for the company.

vTv Therapeutics Stock Performance

The firm's 50 day simple moving average is $16.27 and its 200 day simple moving average is $17.47. The firm has a market capitalization of $47.21 million, a price-to-earnings ratio of -4.92 and a beta of 0.58.

vTv Therapeutics (NASDAQ:VTVT - Get Free Report) last announced its quarterly earnings data on Thursday, May 15th. The biotechnology company reported ($0.77) EPS for the quarter, missing the consensus estimate of ($0.73) by ($0.04).

Institutional Trading of vTv Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of VTVT. Geode Capital Management LLC lifted its stake in shares of vTv Therapeutics by 12.9% in the 4th quarter. Geode Capital Management LLC now owns 11,634 shares of the biotechnology company's stock valued at $158,000 after purchasing an additional 1,327 shares during the period. JPMorgan Chase & Co. acquired a new stake in shares of vTv Therapeutics in the fourth quarter valued at about $25,000. Finally, Connective Capital Management LLC acquired a new stake in shares of vTv Therapeutics in the first quarter valued at about $162,000. 17.51% of the stock is currently owned by institutional investors and hedge funds.

vTv Therapeutics Company Profile

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.